Effect of risperidone on the fluoxetine-induced changes in extracellular dopamine, serotonin and noradrenaline in the rat frontal cortex
Authors:
- Krystyna GołembiowskaKGKrystyna Gołembiowska
- Zofia RogóżZRZofia Rogóż
- 1 September 2013
- journal article
- research article
- Published by Springer Nature in Pharmacological Reports
- Vol. 65 (5) , 1144-1151
Abstract
Several clinical reports have documented a beneficial effect of the addition of a low dose of risperidone to the ongoing treatment with antidepressants, in particular selective serotonin reuptake inhibitors, in the treatment of drug resistant depression. The aim of our study was to understand the mechanism of the clinical efficacy of a combination of fluoxetine (FLU) and risperidone (RIS) in drug-resistant depression. We studied the effect of FLU and RIS, given separately or jointly on the extracellular levels of dopamine (DA), serotonin (5-HT) and noradrenaline (NA) in the rat frontal cortex. Animals were given single intraperitoneal injections of RIS at a doses of 0.1 or 1 mg/kg and FLU at a dose of 10 mg/kg. The release of DA, 5-HT and NA in the rat frontal cortex was investigated using microdialysis in freely moving animals. The extracellular level of DA, 5-HT and NA was assayed by HPLC with coulochemical detection. RIS (0.1 and 1 mg/kg) and FLU (10 mg/kg) increased the extracellular level of cortical DA, 5-HT and NA. Co-treatment of both drugs was more effective in increasing DA release than administration of each of the drugs alone at doses of RIS 1 mg/kg and FLU 10 mg/kg. Co-treatment of FLU and RIS 0.1 mg/kg was more potent than FLU alone, while the effect of joint injection of FLU and RIS 1 mg/kg was stronger than RIS 1 mg/kg alone on 5-HT release. The combination of FLU with both doses of RIS was not effective in increasing NA release as compared to drugs given alone. Our data indicate that the effect of the combined administration of RIS and FLU on DA and 5-HT release in the rat frontal cortex may be of crucial importance to the pharmacotherapy of drug resistant depression.Keywords
Funding Information
- POIG (01.01.02-12-004/09-00)
- European Regional Development Fund
This publication has 52 references indexed in Scilit:
- Augmentation with Atypical Antipsychotics for Depression: A Review of Evidence‐Based Support from the Medical LiteraturePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2013
- A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depressionJournal of Psychiatric Research, 2009
- Augmentation of antidepressants with atypical antipsychotics for treatment‐resistant major depressive disorderActa Psychiatrica Scandinavica, 2008
- Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind ContinuationNeuropsychopharmacology, 2006
- Binding of antipsychotic drugs to human brain receptorsLife Sciences, 2000
- Synergistic Effects of Olanzapine and Other Antipsychotic Agents in Combination with Fluoxetine on Norepinephrine and Dopamine Release in Rat Prefrontal CortexNeuropsychopharmacology, 2000
- Fluoxetine Increases Extracellular Dopamine in the Prefrontal Cortex by a Mechanism Not Dependent on SerotoninJournal of Neurochemistry, 1999
- Fluoxetine increases norepinephrine release in rat hypothalamus as measured by tissue levels of MHPG-SO4 and microdialysis in conscious ratsJournal of Neural Transmission, 1997
- In vivo biogenic amine efflux in medial prefiontal cortex with imipramine, fluoxetine, and fluvoxamineSynapse, 1994
- Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid from rat striatumLife Sciences, 1992